Heparin‐Induced Thrombocytopenia (HIT) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 

Heparin‐induced thrombocytopenia (HIT) is a potentially devastating immune-mediated adverse drug reaction caused by the emergence of antibodies that activate platelets in the presence of heparin. Despite thrombocytopenia, bleeding is rare; HIT is strongly associated with thromboembolic complications involving both the arterial and venous systems. Heparin is widely used for thromboprophylaxis or treatment in many clinical situations, including cardiovascular and orthopedic surgery and invasive procedures, acute coronary syndromes, venous thromboembolism, atrial fibrillation, peripheral occlusive disease, dialysis, and during extracorporeal circulation. Heparin‐induced thrombocytopenia (HIT) is the most important and frequent drug‐induced type of thrombocytopenia. It is associated with significant morbidity and mortality if unrecognized. Unfortunately, because thrombocytopenia is common in hospitalized patients and can be caused by various factors, HIT often remains unrecognized and undiagnosed. HIT develops in two distinct forms: type I and type II. HIT type I is a non‐immunologic response to heparin treatment, mediated by a direct interaction between heparin and circulating platelets, causing platelet clumping or sequestration.

• HIT type I affects up to 10% of patients, usually occurs within the first 48–72 hours after initiation of heparin treatment and is characterized by mild and transient thrombocytopenia, often returning to normal within four days once the heparin is withdrawn.

 

Thelansis’s “Heparin‐Induced Thrombocytopenia (HIT) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Heparin‐Induced Thrombocytopenia (HIT) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Heparin‐Induced Thrombocytopenia (HIT) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Heparin‐Induced Thrombocytopenia (HIT) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Heparin‐Induced Thrombocytopenia (HIT) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033